Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Post by prophetoffactzon Jun 19, 2024 8:43am
133 Views
Post# 36095613

Safety/tolerability profile

Safety/tolerability profileIt's been three weeks as of today since CZO reported its Q1 results and that all single dose levels of the avenanthramide pill to 960mg had been administered without a serious adverse event. These patients had to stay in a hospital for three days so there was no guarentee there wouldn't be serious issues. The Data Safety Monitoring Board was expected to make their decision soon concerning moving to the multi-dose portion of the clinical trial. Will we get a clean safety/tolerability profile? It would be an important step if we did given side-effects of competitors. Having a natural product with a clean safety/tolerability profile could be a competitive advantage.

Perplexity Ai: 
 


Avenanthramides, the polyphenolic compounds found in oats, have been shown to have potent antioxidant, anti-inflammatory, and anti-itch properties, with no significant side effects reported in the available research
.Some key points about the safety and side effects of avenanthramides:
  • Avenanthramides are bioavailable in humans and have been shown to have antioxidant activity after acute consumption of an enriched mixture.
  • Topical application of 1-3 ppm avenanthramides mitigated inflammation in animal models without causing any adverse effects.
  • 8 weeks of dietary avenanthramide supplementation effectively reduced exercise-induced muscle damage, inflammation, and pain in young men and women, with no reported side effects.
  • The anti-inflammatory effects of avenanthramides are attributed to their ability to inhibit NF-κB activation and reduce pro-inflammatory cytokines, without causing toxicity.
  • Avenanthramides have been used for centuries as a soothing agent to relieve itch and irritation associated with various skin conditions, again without any reported side effects.
In summary, the available evidence suggests that avenanthramides are safe and well-tolerated, with no significant side effects reported in the literature. Their potent antioxidant and anti-inflammatory properties make them a promising natural compound for various health applications.
<< Previous
Bullboard Posts
Next >>